Ulrich Herrlinger
Ulrich Herrlinger
Unknown affiliation
No verified email
Cited by
Cited by
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas
KS Aboody, A Brown, NG Rainov, KA Bower, S Liu, W Yang, JE Small, ...
Proceedings of the National Academy of Sciences 97 (23), 12846-12851, 2000
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre …
R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ...
The lancet oncology 15 (10), 1100-1108, 2014
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
E Thiel, A Korfel, P Martus, L Kanz, F Griesinger, M Rauch, A Röth, ...
The lancet oncology 11 (11), 1036-1047, 2010
SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro …
M Uhl, S Aulwurm, J Wischhusen, M Weiler, JY Ma, R Almirez, ...
Cancer research 64 (21), 7954-7961, 2004
Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients
W Küker, T Nägele, A Korfel, S Heckl, E Thiel, M Bamberg, M Weller, ...
Journal of neuro-oncology 72 (2), 169-177, 2005
MRI features of primary central nervous system lymphomas at presentation
U Bühring, U Herrlinger, T Krings, R Thiex, M Weller, W Küker
Neurology 57 (3), 393-396, 2001
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
A Wick, J Felsberg, JP Steinbach, U Herrlinger, M Platten, B Blaschke, ...
Journal of Clinical Oncology 25 (22), 3357-3361, 2007
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
K Hoang-Xuan, E Bessell, J Bromberg, AF Hottinger, M Preusser, R Rudà, ...
The Lancet Oncology 16 (7), e322-e332, 2015
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 …
MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ...
The Lancet 390 (10103), 1645-1653, 2017
MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial
M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ...
Clinical cancer research 21 (9), 2057-2064, 2015
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a …
U Herrlinger, T Tzaridis, F Mack, JP Steinbach, U Schlegel, M Sabel, ...
The lancet 393 (10172), 678-688, 2019
Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report
SA Grimm, JS Pulido, K Jahnke, D Schiff, AJ Hall, TN Shenkier, T Siegal, ...
Annals of oncology 18 (11), 1851-1855, 2007
Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis
W Küker, S Gaertner, T Nägele, C Dopfer, M Schöning, J Fiehler, ...
Cerebrovascular Diseases 26 (1), 23-29, 2008
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F] fluoroethyl)-L-tyrosine PET
N Galldiks, V Dunkl, G Stoffels, M Hutterer, M Rapp, M Sabel, ...
European journal of nuclear medicine and molecular imaging 42 (5), 685-695, 2015
German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma
U Herrlinger, M Schabet, W Brugger, RD Kortmann, W Küker, M Deckert, ...
Annals of Neurology: Official Journal of the American Neurological …, 2002
NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma
U Herrlinger, W Küker, M Uhl, HP Blaicher, HO Karnath, L Kanz, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo
A Jacobs, JG Tjuvajev, M Dubrovin, T Akhurst, J Balatoni, B Beattie, ...
Cancer research 61 (7), 2983-2995, 2001
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy
CM Kramm, M Chase, U Herrlinger, A Jacobs, PA Pechan, NG Rainov, ...
Human gene therapy 8 (17), 2057-2068, 1997
Primary CNS lymphoma with intraocular involvement: international PCNSL collaborative group report
SA Grimm, CA McCannel, AMP Omuro, AJM Ferreri, JY Blay, EA Neuwelt, ...
Neurology 71 (17), 1355-1360, 2008
Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas
U Herrlinger, C Woiciechowski, M Sena-Esteves, KS Aboody, AH Jacobs, ...
Molecular Therapy 1 (4), 347-357, 2000
The system can't perform the operation now. Try again later.
Articles 1–20